Targeted Oncology9m
LP-184 Earns 3 FDA Rare Pediatric Disease Designations in Solid Tumors
The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, ...
Targeted Oncology14m
Axatilimab in Refractory/Recurrent cGVHD: A Promising Later-Line Option
Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent ...
Targeted Oncology15m
Advancing to Third-Line Therapy: Belumosudil in cGVHD
Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease ...
Targeted Oncology39m
Building on the Success of Osimertinib in EGFR-Mutated NSCLC
Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...